Business Context and Reporting Period
Company: Omeros Corp
Filing Type: Form 8-K (Current Report)
Date of Report: August 1, 2013
Event: Submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA).
Key Financial Metrics
This filing does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity. The document is a current report focused on a regulatory event rather than a periodic financial statement.
Material Changes and Events
- Regulatory Submission: On August 1, 2013, Omeros submitted an NDA for the drug candidate OMS302.
- Indication: The application seeks approval for use in patients undergoing intraocular lens replacement surgery.
- Reference: A press release detailing this event is attached as Exhibit 99.1.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future performance, or a discussion of specific risks and contingencies beyond the inherent uncertainty of the FDA approval process implied by the NDA submission.
Investor Verification Checklist
- Verify the status of the FDA review for OMS302 following the August 1, 2013 submission.
- Review the full text of the press release (Exhibit 99.1) for additional details on the clinical data supporting the NDA.
- Check subsequent filings for any FDA responses, Complete Response Letters, or approval decisions.